文献速递核素与放射性配体治疗放射性药物与辐射防护

首届NRG肿瘤学-美国国家癌症研究所系统性放射性药物治疗剂量学研讨会概述

Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy.
PubMed 文献 · J Nucl Med · 2020-12-04

2018年美国国家癌症研究所与NRG肿瘤学首次联合举办系统性放射性药物治疗剂量学研讨会,聚焦临床试验中的剂量学方法、优化剂量报告的策略及新型放射性核素与载体的剂量学需求。文章综述了全身、器官、亚器官和体素等不同空间尺度的吸收剂量计算方法,并探讨剂量学作为生物标志物推动精准医学及优化临床试验设计的路径。

要点

  • 剂量学计算可在全身、器官、亚器官和体素尺度进行,后三者可在MIRD框架内用S值实现。
  • 剂量学方法学与工具进步使其成为系统性放射性药物治疗的最优生物标志物。
  • 剂量学可优化治疗的生物学效应和试验设计,降低药物审批过程中的财务与物流成本。

核心结论

  • 方法学与相关工具的进步已使剂量学成为系统性放射性药物治疗的最优生物标志物。

研究设计与样本

  • 2018年美国国家癌症研究所与NRG肿瘤学首次联合举办研讨会,聚焦系统性放射性药物治疗的剂量学问题与未来临床试验策略。

主要发现

  • 文章综述了临床用于计算吸收剂量的主要方法,包括全身、器官、亚器官和体素等不同空间尺度的吸收剂量计算。
  • 亚器官和体素剂量可在MIRD框架内通过S值计算,可采用解析方法或蒙特卡罗方法,后者在多数情况下使用。

关键数值与推荐

  • 亚器官和体素尺度的吸收剂量可在MIRD框架内用S值计算,并可用解析方法或蒙特卡罗方法实现。

临床怎么用

  • 剂量学可用于优化系统性放射性药物治疗的生物学效应和临床试验设计,以降低药物审批过程中的财务与物流成本。
  • 剂量学等效生物标志物有望在早期试验证据支持下推动系统性放射性药物治疗的精准医学实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2018, the National Cancer Institute and NRG Oncology partnered for the first time to host a joint workshop on systemic radiopharmaceutical therapy (RPT) to specifically address dosimetry issues and strategies for future clinical trials. The workshop focused on current dosimetric approaches for clinical trials, strategies under development that would optimize dose reporting, and future desired or optimized approaches for novel emerging radionuclides and carriers in development. In this article, we review the main approaches that are applied clinically to calculate the absorbed dose. These include absorbed doses calculated over a variety of spatial scales, including whole body, organ, suborgan, and voxel, the last 3 of which are achievable within the MIRD schema (S value) and can be calculated with analytic methods or Monte Carlo methods, the latter in most circumstances. This article will also contrast currently available methods and tools with those used in the past, to propose a pathway whereby dosimetry helps the field by optimizing the biologic effect of the treatment and trial design in the drug approval process to reduce financial and logistical costs. We also briefly discuss the dosimetric equivalent of biomarkers to help bring a precision medicine approach to RPT implementation when merited by evidence collected during early-phase trial investigations. Advances in the methodology and related tools have made dosimetry the optimum biomarker for RPT.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Roncali E, Capala J, Benedict SH, et al. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. J Nucl Med. 2020. PMID: 33277396. doi:10.2967/jnumed.120.255547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。